A markov model study on the hierarchical prognosis and risk factors in patients with chronic kidney disease

Proceedings - 2012 International Conference on Computer Science and Electronics Engineering, ICCSEE 2012

Volumn 2, Issue , 2012, Pages 334-338

  Liu, Xun ^a,b   Lv, Linsheng ^a   Ling, Li ^a   Lou, Tanqi ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Kidney disease chronic; Multi state Markov model; Prognosis; Risk factor

Indexed keywords

CHRONIC KIDNEY DISEASE; END STAGE RENAL DISEASE; IMPACT FACTOR; INFLUENCING FACTOR; KIDNEY DISEASE; MARKOV MODEL; PROGNOSIS; RISK FACTORS;

COMPUTER SCIENCE; DIAGNOSIS; DIALYSIS; ELECTRONICS ENGINEERING; FACTOR ANALYSIS; MARKOV PROCESSES;

PATIENT TREATMENT;

EID: 84861060051     PISSN: None     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1109/ICCSEE.2012.104     Document Type: Conference Paper

References (31)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002 ; 39: S1-266. [PubMed: 11904577]
2. Stevens PE, O'Donoghue DJ, de Lusignan S, Van Vlymen J, Klebe B, Middleton R, et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int 2007; 72: 92-99. [PubMed: 17440495]
3. Modi GK, Jha V. The incidence of end-stage renal disease in India: a population-based study. Kidney Int 2006;70:2131-2133. [PubMed: 17063176]
4. Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, Narita M, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int 2007; 71:159-166. [PubMed: 17136030]
5. Hsu CY, McCulloch CE, Darbinian J, Go AS, Iribarren C. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005;165:923-928. [PubMed: 15851645]
6. Iseki K, Tozawa M, Ikemiya Y, Kinjo K, Iseki C, Takishita S. Relationship between dyslipidemia and the risk of developing end-stage renal disease in a screened cohort. Clin Exp Nephrol 2005;9:46-52. [PubMed: 15830273]
7. Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003;14:2084-2091. [PubMed: 12874462]
8. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004; 44:642-650. [PubMed: 15384015]
9. Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 2004;65:1870-1876. [PubMed: 15086929]
10. Iseki K, Ikemiya Y, Iseki C, Takishita S. Haematocrit and the risk of developing end-stage renal disease. Nephrol Dial Transplant 2003; 18: 899-905. [PubMed: 12686662]
11. Kiberd BA, Clase CM. Cumulative risk for developing end-stage renal disease in the US population: J Am Soc Nephrol 2002;13:1635-1644. [PubMed: 12039993]
12. Iseki K, Iseki C, Ikemiya Y, Fukiyama K. Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int 1996;49:800-805. [PubMed: 8648923]
13. Kannel WB, Stampfer MJ, Castelli WP, Verter J. The prognostic significance of proteinuria: the Framingham study. Am Heart J 1984; 108:1347-1352. [PubMed: 6496291]
14. Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, et al. NSAID use and progression of chronic kidney disease. Am J Med 2007;120:280.e1-7. [PubMed: 17349452]
15. Raffaitin C, Lasseur C, Chauveau P, Barthe N, Gin H, Combe C, et al. Nutritional status in patients with diabetes and chronic kidney disease: a prospective study. Am J Clin Nutr 2007; 85:96-101. [PubMed: 17209183]
16. Bellizzi V, Di Iorio BR, De Nicola L, Minutolo R, Zamboli P, Trucillo P, et al. Very low protein diet supplemented with ketoanalogs improves blood pressure control in chronic kidney disease. Kidney Int 2007; 71:245-251. [PubMed: 17035939]
17. Levey AS, Greene T, Sarnak MJ, Wang X, Beck GJ, Kusek JW, et al. Effect of dietary protein restriction on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis 2006;48:879-888. [PubMed: 17162142]
18. Furth SL, Cole SR, Fadrowski JJ, Gerson A, Pierce CB, Chandra M, et al. The association of anemia and hypoalbuminemia with accelerated decline in GFR among adolescents with chronic kidney disease. Pediatr Nephrol 2007; 22: 265-271. [PubMed:] 17120062
19. Zhou H, Isaman DJ, Messinger S, Brown MB, Klein R, Brandle M, et al. A computer simulation model of diabetes progression, quality of life, and cost. Diabetes Care 2005; 28:2856-2863. [PubMed:] 16306545
20. Murakami Y, Ohashi Y. Projected number of diabetic renal disease patients among insulin-dependent diabetes mellitus children in Japan using a Markov model with probabilistic sensitivity analysis. Int J Epidemiol 2001; 30:1078-1083. [PubMed: 11689526]
21. Tung TH, Chen SJ, Shih HC, Chou P, Li AF, Shyong MP, et al. Assessing the natural course of diabetic retinopathy: a population-based study in Kinmen, Taiwan. Ophthalmic Epidemiol.2006; 13:327-333. [PubMed: 17060111]
22. Liu WJ, Lee LT, Yen MF, Tung TH, Williams R, Duffy SW, et al. Assessing progression and efficacy of treatment for diabetic retinopathy following the proliferative pathway to blindness: implication for diabetic retinopathy screening in Taiwan. Diabet Med 2003; 20:727-733. [PubMed: 12925052]
23. Ragnarson Tennvall G, Apelqvist J. Prevention of diabetes-related foot ulcers and amputations: a cost-utility analysis based on Markov model simulations. Diabetologia 2001;44:2077-2087. [PubMed: 11719840]
24. Rauner MS, Heidenberger K, Pesendorfer EM. Model-based evaluation of diabetic foot prevention strategies in Austria. Health Care Manag Sci 2005;8: 253-265. [PubMed: 16379409]
25. Ortegon MM, Redekop WK, Niessen LW. Cost-effectiveness of prevention and treatment of the diabetic foot: a Markov analysis. Diabetes Care 2004;27:901-7. [PubMed: 15047646]
26. TreeAge Soft, Inc. TreeAge Pro Suite. 2009. www.treeage.com/products/ index.html. Accessed 10 January 2010.
27. ISPED. MKVPCI 1.0. www.isped.u-bordeaux2.fr/RECHERCHE/BIOSTATS/ Telechargement/MKVPCI/US-Biostats-MKVPCI-Guide-utilisateur.htm. Accessed 10 January 2010.
28. Olschewski M, Schumacher M. Statistical analysis of quality of life data in cancer clinical trials.Stat Med 1990; 9:749-763. [PubMed: 2218178]
29. Cox DR, Fitzpatrick R, Fletcher AE, Gore SM, Spiegelhalter DJ, Jones DR. Quality of life assessment: can we keep it simple. J R Stat Soc Ser A 1992; 15:353-393.
30. Dancourt V, Quantin C, Abrahamowicz M, Binquet C, Alioum A, Faivre J. Modeling recurrence in colorectal cancer, J Clin Epidemiol 2004;57:243-251. [PubMed: 15066684]
31. Sweeting MJ, De Angelis D, Neal KR, Ramsay ME, Irving WL, Wright M, et al. Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment. J Clin Epidemiol 2006;59:144-152. [PubMed: 16426949]